• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab.

作者信息

Bhutani Divaya, Assal Amer, Mapara Markus Y, Prinzing Samantha, Lentzsch Suzanne

机构信息

Division of Hematology and Oncology, Columbia University Medical Center, New York, NY.

Division of Hematology and Oncology, Columbia University Medical Center, New York, NY.

出版信息

Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e155-e157. doi: 10.1016/j.clml.2020.01.016. Epub 2020 Feb 4.

DOI:10.1016/j.clml.2020.01.016
PMID:32098724
Abstract
摘要

相似文献

1
Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab.病例报告：卡非佐米诱导的伴有补体激活的血栓性微血管病经依库珠单抗成功治疗
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e155-e157. doi: 10.1016/j.clml.2020.01.016. Epub 2020 Feb 4.
2
Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.两例多发性骨髓瘤患者使用依库珠单抗成功治疗卡非佐米诱导的血栓性微血管病。
BMC Nephrol. 2021 Jan 18;22(1):32. doi: 10.1186/s12882-020-02226-5.
3
Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.补体作为卡非佐米诱导的血栓性微血管病的促成因素。
Br J Haematol. 2021 Apr;193(1):181-187. doi: 10.1111/bjh.16796. Epub 2020 May 29.
4
[Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].[卡非佐米诱导的溶血性尿毒症综合征：依库珠单抗治疗效果良好]
Nephrol Ther. 2020 Jul;16(4):221-224. doi: 10.1016/j.nephro.2020.03.006. Epub 2020 Jun 19.
5
The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.依库珠单抗在犬咬二氧化碳嗜纤维菌相关血栓性微血管病中的应用：一例报告
BMC Infect Dis. 2021 Feb 1;21(1):137. doi: 10.1186/s12879-021-05789-2.
6
[Not Available].[无可用内容]
Cancer Rep (Hoboken). 2024 Oct;7(10):e2163. doi: 10.1002/cnr2.2163.
7
Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.依库珠单抗治疗异基因造血细胞移植相关血栓性微血管病的成人患者
Bone Marrow Transplant. 2016 Sep;51(9):1241-4. doi: 10.1038/bmt.2016.87. Epub 2016 Apr 11.
8
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.依库珠单抗清除率的可变性需要进行药效学监测，以优化造血干细胞移植后血栓性微血管病的治疗。
Biol Blood Marrow Transplant. 2016 Feb;22(2):307-315. doi: 10.1016/j.bbmt.2015.10.002. Epub 2015 Oct 9.
9
The alternative pathway of complement and the thrombotic microangiopathies.补体替代途径与血栓性微血管病
Transfus Apher Sci. 2016 Apr;54(2):220-31. doi: 10.1016/j.transci.2016.04.012. Epub 2016 Apr 26.
10
The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.依库珠单抗在他克莫司诱导的血栓性微血管病中的应用。
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620947266. doi: 10.1177/2324709620947266.

引用本文的文献

1
Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management.卡非佐米治疗多发性骨髓瘤：揭示心脏毒性——从机制到诊断与管理
Front Pharmacol. 2025 Mar 27;16:1570017. doi: 10.3389/fphar.2025.1570017. eCollection 2025.
2
Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis.蛋白酶体抑制剂相关血栓性微血管病：一项真实世界回顾性和药物警戒数据库分析。
Support Care Cancer. 2025 Feb 13;33(3):184. doi: 10.1007/s00520-025-09219-w.
3
Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review.
多发性骨髓瘤患者长期使用卡非佐米治疗后血栓性微血管病（TMA）延迟发作：病例报告及综述
Pharmaceuticals (Basel). 2024 Dec 20;17(12):1722. doi: 10.3390/ph17121722.
4
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review.蛋白酶体抑制剂相关的血栓性微血管病：系统全面的综述。
Blood Cancer J. 2024 Nov 7;14(1):196. doi: 10.1038/s41408-024-01182-9.
5
[Not Available].[无可用内容]
Cancer Rep (Hoboken). 2024 Oct;7(10):e2163. doi: 10.1002/cnr2.2163.
6
Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.多发性骨髓瘤中的微血管病：一例因卡非佐米引起的继发性血栓性微血管病，经血浆置换和补体抑制成功治疗。
BMC Nephrol. 2023 Jun 19;24(1):179. doi: 10.1186/s12882-023-03228-9.
7
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.多发性骨髓瘤患者中卡非佐米诱导的血栓性微血管病的旁路途径基因突变。
Blood Cancer J. 2023 Feb 27;13(1):31. doi: 10.1038/s41408-023-00802-0.
8
Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management.药物性血栓性微血管病：致病药物、病理生理学及管理的最新综述
Front Pharmacol. 2023 Jan 9;13:1088031. doi: 10.3389/fphar.2022.1088031. eCollection 2022.
9
Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.2例多发性骨髓瘤患者同时发生卡非佐米诱导的血栓性微血管病
Fed Pract. 2022 Aug;39(Suppl 3):S56-S62. doi: 10.12788/fp.0284. Epub 2022 Jun 16.
10
Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis.卡非佐米诱导的血栓性微血管病：聚焦发病机制
J Med Cases. 2022 Jun;13(6):274-280. doi: 10.14740/jmc3932. Epub 2022 Jun 11.